CBCD Applauds Novel Therapeutic Approach to Overcome Mucosal Barrier for Prevention of Herpes

July 31, 2012 - PRLog -- The Center for the Biology of Chronic Disease (CBCD) has learned that a new paper written by Kala Pharmaceuticals’ co-founder Justin Hanes, PhD entitled “Mucus-Penetrating Nanoparticles for Vaginal Drug Delivery Protect Against Herpes Simplex Virus” shows that MPPs improve mucus penetration and drug retention.

What are MPPs?

MPPs are Mucus-Penetrating Nanoparticles, and a particular formulation combined with the anti-herpes drug Acyclovir has shown greater efficacy at one tenth of the dose compared to conventional acyclovir in pre-clinical studies.

Why is this important?

This is significant, because according to Robert Langer, ScD, the David H. Koch Institute Professor at MIT, “Mucosal barriers have been largely overlooked as a limitation for drug efficacy. These data show how Kala’s MPP approach can open up new possibilities for more effective medicines. Kala’s technology can be used to engineer innovative therapies with the size and surface coating properties necessary to dramatically improve drug penetration and retention in mucosal tissues leading to the potential for significantly enhanced therapeutic outcomes.”

The CBCD congratulates Kala Pharmaceuticals on the success of its pre-clinical studies in this regard.

Still, even if these methods prove successful in the long-term, they will not eradicate the herpes virus from those already infected. There is no cure for a herpes infection. The CBCD encourages people to think about that for a moment.

Mike Evans, from the CBCD said, “I wish that more research in these areas was being funded…not just in terms of preventing herpes infection, but in terms of actually curing the disease. I think it is so important to take a look at all possibilities. Ground breaking science is hard to come by these days because the process for funding etc. is so slow.”

As mentioned above, there is no cure for a latent herpes (or other latent) viral infection.

The best way to guard against a latent herpes infection is to boost your immune system. In fact, according to the CDC, herpes outbreaks tend to lessen over time. That’s why the CBCD would like to point out a herpes remedy that boosts the immune system and helps target the dormant, (latent) HSV virus.

“The key to your health is to reduce the level of latent viruses in your body to harmless levels.” – Dr. Hanan Polansky

The name of this antiviral remedy is Gene-Eden-VIR. This all-natural product has scientifically been designed to help the human body maintain low concentrations of the latent herpes virus.

By helping the body’s immune system take aim at the latent herpes virus, people can lower their risk of developing fever blisters, cold sores, or genital herpes symptoms. This is just one reason the CBCD believes Gene-Eden-VIR is an essential product.

Gene-Eden-VIR is highly efficient at targeting the latent herpes virus; each ingredient was chosen through a scientific approach. Scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world to identify the safest, most effective natural ingredients that target the latent forms of both HSV-1 and HSV-2.

Gene-Eden-VIR is very safe. It has been on the market for over three years, and in that time, no side effects have been reported. Each capsule contains a patented formula of five all natural ingredients including selenium, camellia sinesis extract, quercetin, cinnamomum extract, and licorice extract. In addition, each bottle is GMP Certified.

Gene-Eden-VIR is sold online through the Gene-Eden website. Each bottle of Gene-Eden-VIR (a one month’s supply) costs just $34.99.

To learn more about Gene-Eden-VIR, the only product on the market today that helps the body target the latent herpes virus and that is scientifically backed by published material, visit http://www.Gene-Eden.com

The Center for the Biology of Chronic Disease (CBCD, http://www.cbcd.net) is a research center recognized by the IRS as a 501(c)(3) non-for-profit organization. The mission of the CBCD is to advance the research on the biology of chronic diseases, and to accelerate the discovery of treatments for these diseases.

The CBCD published the “Purple” book entitled “Microcompetition with Foreign DNA and the Origin of Chronic Disease” written by Dr. Hanan Polansky. The book presents Dr. Polansky’s highly acclaimed scientific theory on the relationship between the DNA of latent (chronic) viruses and the onset of chronic diseases. Dr. Polansky’s book is available as a free download from the CBCD website.

We invite biologists, virologists, and scientists everywhere to download Dr. Polansky’s book here: http://cbcd.net/.